HR Execs on the Move

TriNetX

www.trinetx.com

 
TriNetX is the global health research network enabling healthcare organizations, biopharmaceutical companies and contract research organizations (CROs) to collaborate, enhance trial design, accelerate recruitment and bring new therapies to market faster. TriNetX combines EMR data such as demographics, diagnoses, procedures, medications, labs, genomics, and deep oncology data with data derived from clinical documentation including discharge summaries, radiology reports, pathology reports, and others, to deliver the industry`s most comprehensive data set for protocol design, feasibility, site selection and patient identification.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.trinetx.com
  • 125 Cambridgepark Drive Suite 500
    Cambridge, MA USA 02140
  • Phone: 857.285.6037

Executives

Name Title Contact Details
Kristen Collins
 Senior Vice President, Sales Profile
Shields Carstarphen
 Chief Commercial Officer Profile
Jesica Freeman
 Vice President Product Management and Marketing Profile
Rachael Thomas Higgins
 VP Pharma R&D Strategy, TriNetX LLC Profile
Erin Compean
 Director, Patient Recruitment Operations Profile

Similar Companies

RenovoRx

RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via our proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. Our lead product candidate, RenovoGem, is a combination of gemcitabine and our patented delivery system regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). Targeted therapy via RenovoTAMP platform safely and without transmission to non-targeted areas, is our primary focus. RenovoRx`s patent portfolio currently includes seven issued US patents and one European patent for ourtechnology with several additional patents pending in the US, Europe, and Asia. After demonstrating a median survival of 27.9 months in Phase 1/2 clinical trials vs. 12-15 months reported in historical studies for this patient population, RenovoRx secured two separate Orphan Drug Designations from the FDA for intra-arterial gemcitabine: pancreatic cancer and bile duct cancer (cholangiocarcinoma). This therapy is being further studied in the currently enrolling Phase 3 TIGeR-PaC clinical trial in pancreatic cancer and has a primary endpoint of overall survival and several secondary endpoints, including quality of life. The Phase 3 TIGeR-PaC clinical trial is enrolling unresectable locally advanced pancreatic cancer patients (LAPC) in the United States.

Genome International Corporation

Genome International Corporation is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cathay Industrial Biotech

Cathay Industrial Biotech Ltd is a Mt Zion, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Lifeprint

Lifeprint is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Joyn Bio

Probiotics for Plants, We design microbes for more sustainable agriculture.